PLG0206 Clinical Trials (2026): 2 Studies for Joint Infection & Prosthetic-joint Infection
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 PLG0206 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Joint Infection & Prosthetic-joint Infection) and 254 total planned enrollment. 1 PLG0206 clinical trial is actively recruiting at 9 U.S. sites across 7 states. Most recent activity: NCT07214311 (Sep 2028).
Where to Participate: All PLG0206 Trial Sites in the U.S. (9 sites across 7 states)
Every actively recruiting PLG0206trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | Clinical Trial Site | Sarasota34239 | NCT07214311 | Map |
| FL | Clinical Trial Site | Tamarac33321 | NCT07214311 | Map |
| MD | Clinical Trial Site | Baltimore21215 | NCT07214311 | Map |
| MA | Clinical Trial Site | Boston02120 | NCT07214311 | Map |
| OH | Clinical Trial Site | Cincinnati45267 | NCT07214311 | Map |
| OH | Clinical Trial Site | Columbus43210 | NCT07214311 | Map |
| PA | Clinical Trial Site | Pittsburgh15232 | NCT07214311 | Map |
| TX | Clinical Trial Site | Edinburg78539 | NCT07214311 | Map |
| WV | Clinical Trial Site | Morgantown26506 | NCT07214311 | Map |
PLG0206 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P2/P3 | 1 | 1 |
Recruiting PLG0206 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07214311 | RETAINEvaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty | P2/P3 | Prosthetic-joint Infection | 240 | Feb 2026 |
PLG0206 clinical trials by indication
Prosthetic-joint Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07214311 | RETAIN | P2/P3 | recruiting | Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty |
Joint Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05137314 | DAIR | P1 | completed | Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA) |
All PLG0206 trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07214311 | RETAIN | Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty | P2/P3 | recruiting | 240 | Peptilogics | Feb 2026 |
| NCT05137314 | DAIR | Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA) | P1 | completed | 14 | Peptilogics | Mar 2022 |
PLG0206 clinical trials: frequently asked questions
- How many PLG0206 clinical trials are there?
- 2 PLG0206 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 1 is marked completed.
- Are PLG0206 clinical trials recruiting in 2026?
- Yes — 1 PLG0206 trial is actively recruiting in 2026, with 9 U.S. sites across 7 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is PLG0206 being studied for?
- PLG0206 is being studied for Joint Infection, Prosthetic-joint Infection. The trials are grouped by indication on this page.
- What phase is PLG0206 in?
- PLG0206 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors PLG0206 clinical trials?
- The lead sponsor across the most PLG0206 trials is Peptilogics. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming PLG0206as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: